REVIEW PAPER
Genetic polymorphisms in the pathogenesis and course of Crohn’s disease
1
Department of Digestive Tract Diseases, Norbert Barlicki Memorial University Hospital, Lodz, Poland
Submission date: 2023-04-23
Final revision date: 2023-09-13
Acceptance date: 2023-11-13
Publication date: 2023-12-30
Corresponding author
Oliwia Gocel
Oliwia Gocel Department of Digestive Tract Diseases Norbert Barlicki Memorial University Hospital Lodz, Poland
Oliwia Gocel Department of Digestive Tract Diseases Norbert Barlicki Memorial University Hospital Lodz, Poland
Medical Studies 2023;39(4):396-404
KEYWORDS
TOPICS
ABSTRACT
Crohn’s disease is a chronic inflammatory disease that affects the full length of the digestive tract. The precise aetiology is still unknown, but genetic, environmental, and immunologic factors are involved. The aim of this article is to summarize the current susceptibility genes and gene polymorphisms involved in the disease pathogenesis and clinical course. In recent studies an association was found between FUT2, ATG16L-1, IL-10, TLR, and NOD2 gene mutations and Crohn’s disease. Each of them may affect the disease at a different stage of immune response, are involved in bacterial identification, or are related to bacterial dysbiosis. We present their effect of disease susceptibility, age of onset, severity, risk of surgery, and concomitant infections. Further research in this area may prove useful in early diagnosis, prognosis, and treatment of Crohn’s disease.
REFERENCES (56)
1.
Ferré MPB, Boscá-Watts MM, Pérez MM. Enfermedad de Crohn. Med Clín 2018; 151: 26-33.
2.
Łodyga M, Eder P, Gawron-Kiszka M, Dobrowolska A, Gonciarz M, Hartleb M, Kłopocka M, Małecka-Wojciesko E, Radwan P, Reguła J, Zagórowicz E, Rydzewska G. Guidelines for the management of patients with Crohn’s disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. Gastroenterology Rev 2021; 16: 257-296.
3.
Solà-Tapias N, Vergnolle N, Denadai-Souza A, Barreau F. The interplay between genetic risk factors and proteolytic dysregulation in the pathophysiology of inflammatory bowel disease. J Crohn’s Colitis 2020; 14: 1149-1161.
4.
Dessein R, Chamaillard M, Danese S. Innate immunity in Crohn’s disease: the reverse side of the medal. J Clin Gastroenterol 2008; 42 Suppl: S144-S147.
5.
Turpin W, Goethel A, Bedrani L, Croitoru K. Determinants of IBD heritability: genes, bugs, and more, Inflamm Bowel Dis 2018; 24: 1133-1148.
6.
Moller FT, Andersen V, Wohlfahrt J, Jess T. Familial risk of inflammatory bowel disease: a population-based cohort study 1977-2011. Am J Gastroenterol 2015; 110: 564-571.
7.
Spehlmann ME, Begun AZ, Burghardt J, Lepage P, Raedler A, Schreiber S. Epidemiology of inflammatory bowel disease in a German twin cohort: results of a nationwide study. Inflamm Bowel Dis 2008; 14: 968-976.
8.
Zhao M, Gönczi L, Lakatos PL, Burisch J. The burden of inflammatory bowel disease in Europe in 2020. J Crohn’s Colitis 2021; 15: 1573-1587.
9.
Ismail S, Essawi M. Genetic polymorphism studies in humans. Middle East J Med Genetics 2012; 1: 57-63.
10.
Giampaoli O, Conta G, Calvani R, Miccheli A. Can the FUT2 non-secretor phenotype associated with gut microbiota increase the children susceptibility for type 1 diabetes? A mini review. Front Nutrition 2020; 7: 606171.
11.
O’Brien SJ, Hallion J, Scheurlen KM, Fiechter C, Burton J, Paas M, Schmidt M, Gardner S, Eichenberger MR, Pan J, Rai S, Galandiuk S. Crohn’s disease-related single nucleotide polymorphisms are associated with ileal pouch afferent limb stenosis. J Gastrointest Surg 2021; 25: 2377-2386.
12.
McGovern DPB, Jones MR, Taylor KD, et al. Fucosyltransferase 2 (FUT2) non- secretor status is associated with Crohn’s disease. Hum Mol Genet 2010; 19: 3468-3476.
13.
Ye BD, Kim BM, Jung S, Lee HS, Hong M, Kim K, Moon JW, Baek J, Oh EH, Hwang SW, Park SH, Yang SK, Song K. Association of FUT2 and ABO with Crohn’s disease in Koreans. J Gastroenterol Hepato. 2020; 35: 104-109.
14.
Wu H, Sun L, Lin DP, Shao XX, Xia SL, Lv M. Associon of fucosyltransferase 2 gene polymorphisms with inflammatory bowel disease in patients from Southeast China. Gastroenterol Res Pract 2017; 2017: 4148651.
15.
Tang X, Wang W, Hong G, Duan C, Zhu S, Tian Y, Han C, Qian W, Lin R, Hou X. Gut microbiota-mediated lysophosphatidylcholine generation promotes colitis in intestinal epithelium-specific Fut2 deficiency. J Biomed Sci 2021; 28: 20.
16.
Pugazhendhi S, Baskaran K, Santhanam S, Ramakrishna BS. Association of ATG16L1 gene haplotype with inflammatory bowel disease in Indians. PLoS One 2017; 12: e0178291.
17.
Haq S, Grondin J, Banskota S, Khan WI. Autophagy: roles in intestinal mucosal homeostasis and inflammation. J Biomed Sci 2019; 26: 19.
18.
Aida I, Meddour Y, Kadiri H, Smara M, Bousseloub A, Kecili L, Gamar L, Belhocine K, Boussafsaf MA, Debzi N, Aouichat-Bouguerra S, Chaib S. T300A variant of AT16L1 gene in a cohort of Algerian Crohn disease patients. Curr Res Transl Med 2018; 66: 9-14.
19.
Salem M, Nielsen OH, Nys K, Yazdanyar S, Seidelin JB. Impact of T300A variant ofATG16L1on antibacterial response, risk of culture positive infections, and clinical course of Crohn’s disease. Clin Transl Gastroenterol 2015; 6: e122.
20.
Ngoh E, Brugger H, Monajemi M, Menzies SC, Hirschfeld AF, Del Bel KL, Jacobson K, Lavoie PM,Turvey SE, Sly LM. The Crohn’s disease-associated polymorphism in ATG16L1 (rs2241880) reduces SHIP gene expression and activity in human subjects. Genes Immun 2015; 16: 452-461.
21.
Kim S, Eun HS, Jo EK. Roles of autophagy-related genes in the pathogenesis of inflammatory bowel disease. Cells 2019; 8: 77.
22.
Larabi A, Barnich N, Nguyen HTT. New insights into the interplay between autophagy, gut microbiota, and inflammatory responses in IBD, Autophagy 2020; 16: 38-51. .
23.
Ghavami SB, Kabiri F, Nourian M, Balaii H, Shahrokh S, Chaleshi V, Sherkat G, Shalileh F, Aghdaei HA. Association between variants of the autophagy related gene ATG16L1 in inflammatory bowel diseases and clinical statues. Gastroenterol Hepatol Bed Bench 2019; 12 (Suppl 1): S94-S100.
24.
Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10, and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765.
25.
Neumann C, Scheffold A, Rutz S. Functions, and regulation of T cell-derived interleukin-10. Semin Immunol 2019; 44: 101344.
26.
Saraiva M, Vieira P, O’Garra A. Biology, and therapeutic potential of interleukin-10. J Exp Med 2020; 217: e20190418.
27.
Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F, Perro M, Diestelhorst J, Allroth A, Murugan D, Hätscher N, Pfeifer D, Sykora KW, Sauer M, Kreipe H, Lacher M, Nustede R, Woellner C, Baumann U, Salzer U, Koletzko S, Shah N, Segal AW, Sauerbrey A, Buderus S, Snapper SB, Grimbacher B, Klein C. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009; 361: 2033-2045.
28.
Shim JO, Hwang S, Yang HR, Moon JS, Chang JY, Ko JS, Park SS, Kang GH, Kim WS, Seo JK. Interleukin-10 receptor mutations in children with neonatal-onset Crohn’s disease and intractable ulcerating enterocolitis. Eur J Gastroenterol Hepatol 2013; 25: 1235-1240.
29.
Beser OF, Conde CD, Serwas NK, Cokugras FC, Kutlu T, Boztug K, Erkan T. Clinical features of interleukin 10 receptor gene mutations in children with very early-onset inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2015; 60: 332-338. .
30.
Huang Z, Peng K, Li X, Zhao R, You J, Cheng X, Wang Z, Wang Y, Wu B, Wang H, Zeng H, Yu Z, Zheng C, Wang Y, Huang Y. Mutations in interleukin-10 receptor and clinical phenotypes in patients with very early onset inflammatory bowel disease: a Chinese VEO-IBD Collaboration Group Survey. Inflamm Bowel Dis 2017; 23: 578-590.
31.
Moran CJ, Walters TD, Guo CH, Kugathasan S, Klein C, Turner D, Wolters VM, Bandsma RH, Mouzaki M, Za-chos M, Langer JC, Cutz E, Benseler SM, Roifman CM, Silverberg MS, Griffiths AM, Snapper SB, Muise AM. IL-10R polymorphisms are associated with very-early-onset ulcerative colitis. Inflamm Bowel Dis 2013; 19: 115-123.
32.
Xiao Y, Wang XQ, Yu Y, Guo Y, Xu X, Gong L, Zhou T, Li XQ, Xu CD. Comprehensive mutation screening for 10 genes in Chinese patients suffering very early onset inflammatory bowel disease. World J Gastroenterol 2016; 22: 5578-5588.
33.
Kotlarz D, Beier R, Murugan D, Diestelhorst J, Jensen O, Boztug K, Pfeifer D, Kreipe H, Pfister ED, Baumann U, Puchalka J, Bohne J, Egritas O, Dalgic B, Kolho KL, Sauerbrey A, Buderus S, Güngör T, Enninger A, Koda YK, Guariso G, Weiss B, Corbacioglu S, Socha P, Uslu N, Metin A, Wahbeh GT, Husain K, Ramadan D, Al-Herz W, Grimbacher B, Sauer M, Sykora KW, Koletzko S, Klein C. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology 2012; 143: 347-355.
34.
van der Linde K, Boor PP, Sandkuijl LA, Meijssen MA, Savelkoul HF, Wilson JH, de Rooij FW. A Gly15Arg mutation in the interleukin-10 gene reduces secretion of interleukin-10 in Crohn disease. Scand J Gastroenterol 2003; 38: 611-617.
35.
Sharifinejad N, Zaki-Dizaji M, Sepahvandi R, Fayyaz F, dos Santos Vilela MM, ElGhazali G, Abolhassani H, Ochs HD, Azizi G. The clinical, molecular, and therapeutic features of patients with IL10/IL10R defciency: a systematic review. Clin Exp Immunol 2022; 208: 281-291. .
36.
Khoshnevisan R, Vakili F, Klein C, Kotlarz D, Nasirian M, Sherkat R, Rezaei A. An analysis and survey of interleukin-10 receptor mutation in inflammatory bowel disease (IBD) in the first Iranian IBD cohort. J Labor Med 2019; 43: 185-189.
37.
Shim J, Seo J. Very early-onset inflammatory bowel disease (IBD) in infancy is a different disease entity from adult-onset IBD; one form of interleukin-10 receptor mutations. J Hum Genet 2014; 59: 337-341.
38.
Drexler SK, Foxwell BM. The role of toll-like receptors in chronic inflammation. Int J Biochem Cell Biol 2010; 42: 506-518.
39.
Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2: 675-680.
40.
Fukata M, Abreu MT. TLR4 signalling in the intestine in health and disease. Biochem Soc Trans 2007; 35: 1473-1478.
41.
Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140: 805-820.
42.
Candelli M, Franza L, Pignataro G, Ojetti V, Covino M, Piccioni A, Gasbarrini A, Franceschi F. Interaction between lipopolysaccharide and gut microbiota in inflammatory bowel diseases. Int J Mol Sci 2021; 22: 6242.
43.
Wang H, Zhou S, Zhang J, Lei S, Zhou J. Correlations between TLR polymorphisms and inflammatory bowel disease: a meta-analysis of 49 case-control studies. Immunol Rev 2019; 67: 142-150.
44.
Cheng Y, Zhu Y, Huang X, Zhang W, Han Z, Liu S. Association between TLR2 and TLR4 gene polymorphisms and the susceptibility to inflammatory bowel disease: a meta-analysis. PLoS One 2015; 10: e0126803.
45.
Mahla RS, Reddy MC, Prasad DVR, Kumar H. Sweeten PAMPs: role of sugar complexed PAMPs in innate immunity and vaccine biology. Front Immunol 2013; 4: 248.
46.
Brasier AR. The NF-kappaB regulatory network. Cardiovasc Toxicol 2006; 6: 111-130.
47.
Yang E, Shen J. The roles and functions of Paneth cells in Crohn’s disease: a critical review. Cell Prolif 2021; 54: e12958.
48.
Carrière J, Darfeuille-Michaud A, Nguyen HT. Infectious etiopathogenesis of Crohn’s disease. World J Gastroenterol 2014; 20: 12102-12117.
49.
Caruso R, Warner N, Inohara N, Núñez G. (2014, December 18). NOD1 and NOD2: signaling, host defense, and inflammatory disease. Immunity 2014; 41: 898-908.
50.
Lauro ML, Burch JM, Grimes CL. The effect of NOD2 on the microbiota in Crohn’s disease. Curr Opin Biotechnol 2016; 40: 97-102.
51.
Ashton JJ, Seaby EG, Beattie RM, Ennis S. NOD2 in Crohn’s disease – unfinished business. J Crohn’s Colitis 2023; 17: 450-458.
52.
Gajendran M, Loganathan P, Catinella AP, Hashash JG. A comprehensive review and update on Crohn’s disease. Dis Mon 2018; 64: 20-57.
53.
Frade-Proud’Hon-Clerc S, Smol T, Frenois F, Sand O, Vaillant E, Dhennin V, Bonnefond A, Froguel P, Fumery M, Guillon-Dellac N, Gower-Rousseau C, Vasseur F. A novel rare missense variation of the nod2 gene: evidence sof implication in Crohn’s disease. Int J Mol Sci 2019; 20: 835.
54.
Younis N, Zarif R, Mahfouz R. Inflammatory bowel disease: between genetics and microbiota. Mol Biol Rep 2020; 47: 3053-3063.
55.
Adler J, Rangwalla SC, Dwamena BA, Higgins PD. The prognostic power of the NOD2 genotype for complicated Crohn’s disease: a meta-analysis. Am J Gastroenterol 2011; 106: 69-712.
56.
Salkic NN, Adler G, Zawada I, Alibegovic E, Karakiewicz B, Kozlowska-Wiechowska A, Wasilewicz M, Sulzyc-Bielicka V, Bielicki D. NOD2/CARD15 mutations in Polish and Bosnian populations with and without Crohn’s disease: prevalence and genotype-phenotype analysis. Bosnian J Basic Med Sci 2015; 15: 67–72.
Share
RELATED ARTICLE
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
